Drugs / CD83-positive MSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06882811 | May 2025 → Dec 2027 expected | infectious disease with sepsis | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD83-positive MSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06882811 ↗ |
| Modality | Cell therapy | “a single dose of allogeneic umbilical cord-derived mesenchymal stem cells (MSCs)” PMID 30044959 ↗ Apr 2018 |
| Route | Intravenous | “The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis” NCT06882811 ↗ |